Optimized anti-CD30 antibodies

• US 7,973,136 B2
• Filed: 10/06/2006
• Issued: 07/05/2011
• Est. Priority Date: 10/06/2005
• Status: Active Grant

• Current Assignee: Xencor, Inc.
• Original Assignee: Xencor, Inc.
• Inventors: Chu, Seung Y., Carmichael, David F., Chen, Bao-lu, Kunkel, Lori, Lazar, Gregory Alan, Karki, Sher Bahadur, Desjarlais, John R., Hammond, Philip W.
• Primary Examiner(s): GUSSOW, ANNE
• Application Number:
  US12/089,384
• Publication Number:
  US 20080267976A1
• Time in Patent Office: 1,733 Days
• Field of Search: None
• US Class Current: 530/387.1
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/72 Increased effector function due to an Fc-modification
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.

Claims

1. A purified anti-CD30 antibody, said antibody comprising a heavy chain and a light chain,

wherein said heavy chain comprises

a VH CDR1 comprising the amino acid sequence of SEQ ID NO:

23,

a VH CDR2 comprising the amino acid sequence of SEQ ID NO;

30, and

a VH CDR3 comprising the amino acid sequence of SEQ ID NO;

25, and wherein said light chain comprises

a VL CDR1 comprising the amino acid sequence of SEQ ID NO;

33,

a VL CDR2 comprising the amino acid sequence of SEQ ID NO;

34, and

a VL CDR3 comprising the amino acid sequence of SEQ ID NO;

28.

2. The anti-CD30 antibody of claim 1, wherein the heavy chain comprises a variable region comprising an amino acid sequence of SEQ ID NO:

11, and wherein the light chain comprises a variable region comprising an amino acid sequence selected from the group consisting of an amino acid sequence of SEQ ID NO;

10.

3. The anti-CD30 antibody of claim 2, wherein said heavy chain comprises an amino acid sequence of SEQ ID NO:

20 and said light chain comprises an amino acid sequence of SEQ ID NO;

19.

4. A pharmaceutical composition comprising a variant anti-CD30 antibody according to claim 1 and a pharmaceutically acceptable carrier.

5. A method of treating Hodgkin'"'"'s lymphoma comprising administering a anti-CD30 antibody according to claim 1.

6. A method of inhibiting proliferation of a cell expressing CD30, wherein said method comprises contacting said cell with a anti-CD30 antibody according to claim 1.

7. A method of enhancing antibody dependent cell cytotoxicity toward a cell expressing CD30, wherein said method comprises contacting said cell with a anti-CD30antibody according to claim 1.

8. A method of depleting a mammal of at least one cell expressing CD30, wherein said method comprises administering to the mammal a variant anti-CD30antibody according to claim 1.